Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4772 Comments
1384 Likes
1
Bufard
Trusted Reader
2 hours ago
I understood it emotionally, not logically.
👍 121
Reply
2
Korrion
New Visitor
5 hours ago
This feels like a life lesson I didn’t ask for.
👍 159
Reply
3
Panchita
Legendary User
1 day ago
Helpful for anyone looking to stay informed on market developments.
👍 247
Reply
4
Jemarcus
Trusted Reader
1 day ago
This feels like a warning I ignored.
👍 283
Reply
5
Michiye
Loyal User
2 days ago
This feels like step 2 forever.
👍 217
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.